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A B S T R A C T
Advanced Parkinson's disease (APD) is characterized by increased functional disability, caused by motor com-
plications, the presence of axial symptoms, and emergent disease- and drug-related non-motor symptoms. One of
the advanced therapies available is intrajejunal infusion of levodopa/carbidopa intestinal gel (LCIG); however,
patient selection for this treatment is sometimes diﬃcult, particularly because of overlapping indications with
other alternatives.
In recent years, strong evidence has supported the use of LCIG in treating motor ﬂuctuations associated with
APD, and several clinical studies provide emerging evidence for additional beneﬁts of LCIG treatment in certain
patients. This article provides an overview of the published literature on the beneﬁts, limitations, and drawbacks
of LCIG in relation to PD symptoms, the psychosocial impact of the disease, and the quality of life of patients,
with the aim of determining candidates for whom treatment with LCIG would be beneﬁcial. According to current
evidence, patients with APD (deﬁned as inability to achieve optimal control of the disease with conventional oral
treatment), a relatively well-preserved cognitive-behavioral status, and good family/caregiver would count as
suitable candidates for LCIG treatment. Contraindications in the opinion of the authors are severe dementia and
active psychosis.
1. Introduction
The aim of currently available conventional drug treatments of
Parkinson's disease (PD; levodopa, dopamine agonists [DAs], and enzyme
inhibitors) is to enhance dopaminergic transmission [1]. These treatments
greatly improve symptoms of PD in the early and middle stages of the disease
[2–6]. Due to the progressive nature of PD, however, the beneﬁts are
gradually reduced as the symptoms worsen [7,8]. The concept of advanced
PD (APD) is broad, but it is generally associated with motor complications
(ﬂuctuations and dyskinesia that cannot be adequately controlled by standard
medications), increased functional disability, the stage of the disease [9], by
the presence of axial symptoms (gait and balance impairment), and by
emergent disease- and drug-related non-motor symptoms (NMS; mainly
neuropsychiatric complications, including cognitive impairment) [10,11],
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Table 1
Summary of improvement in OFF time, ON time and dyskinesia with LCIG as reported in the literature.
Study Change in OFF time Change in ON time without dyskinesia Change in ON time with dyskinesia
Antonini et al. 2007 [44]
9 patients
Observational
prospective
At 12 months, 9.5-fold reduction.
(mean reduction from 284 to 30 min;
p < 0.01)
Reduced by nearly 4-fold at 6 and 12 months
(mean reduction from 156 to 40 min; p < 0.01)
Antonini et al. 2008 [45]
22 patients
Observational
prospective
UPDRS IV item 39
Baseline: 2.6 ± 1.2
After 1 year 1.28 ± 0.5
After 2 years: 1.48 ± 0.8 (p < 0.05)
No changes in dyskinesia duration No changes in dyskinesia duration
Eggert et al. 2008 [46]
13 patients
Observational
prospective
Percentage of time
Baseline: 50 ± 14%
After 6 months: 11 ± 7% (p < 0.01)
Percentage of time
Baseline: 17 ± 15%
After 6 months: 5 ± 6% (p < 0.01)
Santos-García, 2010 [48]
9 patients
Observational
retrospective
90.9% improvement Daily ON time showed 66.6% improvement
Puente et al. 2010 [49]
9 patients
Observational
retrospective
Reduced from 9.4 ± 2.1 h to
3.1 ± 2.7 h (p < 0.05)
Daily ON time increased from 6.1 ± 1.9 to 12.0 ± 3.4 h (p < 0.05)
Fasano et al. 2012 [52]
14 patients
Observational
retrospective
UPDRS IV item 39 unchanged (−7.6%)
Oﬀ duration reduced by 48.6%
(p= 0.00001)
Reduced by 38.5%
(p= 0.001)
Antonini et al. 2013 [59]
73 patients
Observational
prospective
UPDRS IV item 39. OFF time duration
Baseline 1.59 ± 0.96
Month 6: 0.85 ± 0.63 (p < 0.05)
Month 12: 1.06 ± 0.73 (p < 0.05)
UPDRS IV item 32. Dyskinesia duration
Baseline: 1.72 ± 0.98
Month 6: 1.15 ± 0.87 (p < 0.05)
Month 12: 1.45 ± 0.83 (p < 0.05)
Foltynie et al. 2013 [23]
12 patients
Observational
prospective
Percentage of time
Baseline: 29.4 ± 13.2%
Follow-up 16.7 ± 22.2% (p= 0.06)
Percentage of time
Baseline: 16.6 ± 18.6%
Follow-up 8.2 ± 10.3% (p= 0.22)
Caceres Redondo et al.
2014 [62]
29 patients
Observational
retrospective
UPDRS IV item 39. OFF time duration
Baseline: 58.1 ± 11.5
Follow-up: 24.6 ± 7.2 (p < 0.05)
UPDRS IV item 32. Dyskinesia duration
Baseline: 60.6 ± 37.8
Follow-up: 48.8 ± 28.7 (p < 0.05).
Olanow et al. 2014 [37]
35 patient allocated to
LCIG
Prospective, double-
blind trial
Decreased by 4.04 ± 0.65 h Increased by 4.11 ± 0.75 h Decreased by 1.8 ± 1.3
Slevin et al. 2015 [38]
Open-label extension
of ref. [37]
LCIG-naive: 29
patients
LCIG continuing: 33
patients
LCIG-naïve:
Decreased 2.34 ± 2.78 h (p < 0.001)
LCIG-continuing:
Sustained reduction 0.42 ± 2.67 h
(p= 0.377)
LCIG-naïve:
Increased 2.19 ± 3.70 h (p= 0.005)
LCIG-continuing:
Increased 1.00 ± 2.58 h (p= 0.036)
Pickut et al. 2014 [22]
37 patients
Observational
prospective
UPDRS IV item 39
89.5% of patients experienced improvement
UPDRS IV item 32. Dyskinesia duration
60–70% of patients experienced improvement
Sensi et al. 2014 [35]
28 patients
Observational
prospective
UPDRS IV item 39. OFF time duration
Baseline: 2.3 ± 0.9
24 months: 48% improvement
(p < 0.00001)
UPDRS IV item 32. Dyskinesia duration
Baseline: 2.2 ± 1.1
Signiﬁcant improvement after 24 months
Zibetti et al. 2014 [66]
59 patients
Observational
retrospective
UPDRS IV item 39. OFF time duration
Baseline: 1.8 ± 0.7
Follow-up: 0.9 ± 0.5
Duration reduced by 49%(p < 0.001)
UPDRS IV item 32. Dyskinesia duration
Baseline: 1.7 ± 0.9
Follow-up: 1.2 ± 0.0.7
Duration reduced by 30% (p= 0.002)
Antonini et al. 2015 [70]
56 patients with data
for this analysis
Observational
prospective
Baseline: 7.1 ± 3.5 h
12 months reduced by 4.7 ± 3.4
(p < 0.0001)
Baseline: 5.2 ± 4.5 h
12 months reduced by 1.7 ± 5.0 (p= 0.023)
Buongiorno et al. 2015
[74]
72 patients
Observational
prospective
Baseline: 6.8 ± 2.8 h (45% of day)
Last visit: 3.0 ± 3.5 h (20% of day)
Patients with< 50% at baseline: increased from 18%
to 35% at last visit
Patients with> 50% at baseline: no change
Calandrella et al. 2015
[81]
35 patients
UPDRS IV item 39. OFF time duration
Baseline: 2.4 ± 0.6
Follow-up 1.1 ± 0.6 (p < 0.001)
Dyskinesia score (UPDRS IV items 32–33)
Baseline: 2.2 ± 0.7
Follow-up 1.5 ± 0.7 (p < 0.001)
(continued on next page)
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with onset generally several years after diagnosis [12]. Together, these as-
pects of the disease, heterogeneous and requiring an individualized approach,
lead to progressive disability and impaired quality of life (QoL) for patient
and caregivers [13–16].
In individuals with APD clinicians may consider the use of non-
conventional device-aided alternatives such as deep brain stimulation
(DBS), apomorphine continuous subcutaneous infusion, or intrajejunal
infusion of levodopa/carbidopa intestinal gel (LCIG) [11,17–19]. De-
termining which patients will most likely beneﬁt from these device-
aided therapies can be challenging, particularly because of overlapping
indications. In any event, the invasive nature [20,21] and cost [20–23]
of these therapies make it imperative to assess patient's suitability on a
case-by-case basis [18,19,24].
Pulsatile dopaminergic stimulation with oral levodopa is considered to
play a role in the development of late complications in PD [25,26]. Non-oral
administration of levodopa was developed with the aim of providing more
continuous dopaminergic delivery and overcoming the inherent variability
in absorption related to gastric emptying [18,27]. LCIG requires the pla-
cement of a gastroduodenal tube to elicit continuous infusion and absorp-
tion of the drug bypassing the stomach [1], so that relatively stable plasma
levels of levodopa are achieved [28]. In this regard, pharmacokinetic stu-
dies have established that the degree of ﬂuctuation of levodopa and car-
bidopa plasma concentrations ((Cmax− Cmin)/average concentration) is
very low within hours 2 to 16 in a 16-h long infusion of LCIG (0.52 and 0.96
respectively) [29]. Intra-subject coeﬃcients of variation of these drugs were
also very low in this analysis (13% and 19%, respectively). Additionally,
two studies have reported reduced variability of levodopa levels compared
to oral tablets. Kurth et al. found a reduction from 38 ± 11% with tablets
to 17 ± 9% with infusion) [30], and Nyholm et al. reported a reduction
from 34% intraindividual coeﬃcient of variation with oral tablets to 14%
(p < 0.01) with infusion in a series of 16 patients [31]. This was also
observed in a mixed-eﬀects model characterizing population pharmacoki-
netics, based on results of phase I and phase III trials, that showed similar
bioavailability with half the intra-subject variability, and faster absorption
compared to oral tablets [32]. Such “continuous dopaminergic delivery”
[33] improves motor and potentially some non-motor ﬂuctuations, and
dyskinesias. These symptoms are common in patients undergoing long-term
treatment with oral levodopa, particularly in those with the onset of motor
symptoms before the age of 60 [2]. Although clinical trials have demon-
strated the eﬃcacy and safety of DBS, apomorphine, and LCIG, the choice of
suitable candidates depends on multiple clinical and patient-related vari-
ables [11,21,24,34–41].
No randomized controlled trials have directly compared these three
treatments [18,19,42], and in patients with APD, selection of the most
appropriate therapy is often challenging. In recent years, strong evidence
has supported the use of LCIG in treating motor ﬂuctuations associated with
APD, and several clinical studies provide emerging evidence for additional
beneﬁts of LCIG treatment in certain patients. The aim of this review is to
deﬁne the beneﬁts and drawbacks of treatment with LCIG that may help
identify the proﬁle of suitable candidates.
2. Motor complications: ﬂuctuations and dyskinesias
The progression of PD and the chronic use of oral levodopa are
associated with narrowing of the therapeutic window, leading to motor
complications (ﬂuctuations, dyskinesia). A typical ﬂuctuation is the
end-of-dose or wearing-oﬀ phenomenon; however, more complex and
unpredictable patterns often follow. Dyskinesias include peak-dose and
biphasic dyskinesias during ON time, as well as dystonia during OFF
time. As these complications may result in severe disability, reduction
of OFF time, dyskinesia, and other motor symptoms are of the utmost
importance. The vast majority of patients with PD eligible for device-
aided treatment are currently treated with levodopa with or without
DAs, along with other antiparkinsonian drugs. The lack of success in
controlling motor symptoms and/or the presence of adverse eﬀects due
to high doses or combinations of oral medications deﬁne the eligibility
for patients included in studies of LCIG.
2.1. Motor ﬂuctuations
The continuous absorption of levodopa/carbidopa achieved with
LCIG has been shown to extend ON time maintaining relatively stable
plasma drug levels with less extreme peaks and troughs [29]. Most
Table 1 (continued)
Study Change in OFF time Change in ON time without dyskinesia Change in ON time with dyskinesia
Observational
prospective
Fernandez et al. 2015 [41]
324 patients
Observational
prospective
Baseline: 6.75 ± 2.35 h
12 months: 2.32 ± 2.05 h
(65.6% reduction p= 0.001)
Baseline: 17.4 ± 6.6 h
12 months: +4.8 ± 3.4 h
(62.9% increase; p < 0.001)
Baseline: 1.61 ± 2.03 h
12 months: 1.24 ± 2.10 h
(22.5% increase; p < 0.023)
Chang et al. 2016 [80]
15 patients
Observational
prospective
Reduced from 6.3 ± 2 to 1.9 ± 2 h Increased from 4.5 ± 3 to 7.5 ± 5 h
Băjenaru et al. 2016 [73]
113 patients
Observational
retrospective
Reduced 1.36 h (from 7.5 h to 6.14 h)
(p < 0.0001)
Reduced by 29.4%
Valldeoriola et al. 2016
[65]
117 patients
Observational
retrospective
Baseline 47.6%
LCIG reduced to 16.2%
Baseline 21.6%
LCIG: increased to 55.6%
Timpka et al. 2016 [72]
9 patients
Observational
prospective
112% increase after 6 months (p < 0.01) 47% decrease after 6 months (p < 0.05)
Lopiano et al. 2016 [75]
145 patients (Interim
results)
Observational
prospective
UPDRS IV item 39. OFF time duration
Decreased from 2.1 ± 0.8 to 0.9 ± 0.7
(57% reduction p < 0.0001)
Reduced 28%
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studies have reported positive outcomes in motor complications
[22,23,31,35,37–41,43–75], with reduced duration of OFF time and
increased ON time without disabling dyskinesia (Table 1). Two recent
prospective clinical trials, a double-blind, double-dummy study [37]
and an open-label baseline-controlled study [41], reported a reduction
in OFF time of approximately 4 h per day from the baseline (12 weeks
[37] and 12 months [41], respectively). The ﬁrst of these studies, a
phase III trial published by Olanow et al., reported a signiﬁcantly
greater reduction in OFF time with LCIG (4.04 h) compared with the
reduction in the control group treated with oral levodopa (2.14 h) [37].
Although this study had a short follow-up period, the improvement was
maintained in patients who continued from the double blind study into
the 52-week open-label extension study [38]. Additionally, LCIG-naïve
patients starting treatment in this extension study experienced a re-
duction in OFF time similar to that reported by the LCIG arm in the
double-blind trial. In the Fernandez et al. phase III open-label, baseline-
controlled study [41], a similar 4-h reduction in OFF time in a cohort of
354 patients was reported, representing a signiﬁcant 65.6% improve-
ment in this outcome over a 12-month follow-up period (with 272/354
patients completing the study).
Studies consistently report a signiﬁcant reduction in OFF time,
leaving little doubt regarding the beneﬁcial eﬀects of LCIG in patients
with this complication over long periods of time [22,35,39,41,
44,46–48,52,59,61,66,68,70,73–81]. Furthermore, some studies sug-
gest that LCIG may improve other OFF time-related PD symptoms, such
as dystonic pain [46,82–84] and selected patients with morning aki-
nesia and OFF-related dystonia have also been successfully treated with
24-h infusions [46,85]. Signiﬁcant improvements have also been re-
ported in motor ﬂuctuations, including wearing-oﬀ, delayed ON, no-
ON, unpredictable OFF periods, and morning akinesia [74,75].
Preliminary evidence suggested that the magnitude of improvement
varied with disease duration: in a retrospective national cohort, patients
with disease duration of ≥10 years showed signiﬁcantly less im-
provement in OFF time (28.9% reduction) compared to patients with
PD duration of< 10 years (38% reduction) [86]. However, the recently
reported analysis from the 2-year data of the GLORIA registry suggested
that age (dichotomized into< or ≥65 years) or disease duration (di-
chotomized into< or≥10 years) did not impact outcomes in quality of
life and daily life activities [87], and OFF time reduction was very
stable over the two years. Also, in a post-hoc analysis of baseline
characteristics related to the therapeutic response to LCIG performed in
the open-label phase-III study by Fernandez et al. [41], age and disease
duration did not play a role in OFF time improvement [88]. At any rate,
several studies have shown that, in the absence of severe adverse
events, control of motor ﬂuctuations continues for several years in most
patients [53,66,83].
2.2. Dyskinesias
With regard to improvement in dyskinesia, trials report increases in
ON time with no disabling dyskinesia similar to the reduction in OFF
time (4 h/day) [37,38,41,89]. General improvement is consistent in
retrospective and prospective studies with follow-up periods of up to
2 years, and signiﬁcant reductions in ON time with troublesome dys-
kinesia have also been reported [46,48,52,59,61,69,70,72,73,
75,79,90]. However, this improvement seems to be heterogeneous.
Some studies describe a signiﬁcant improvement in nearly all patients
[47,69], while others report a worsening of disease in some patients
[74,91]. A recent study of 72 patients found that in individuals with
dyskinesia for< 50% of the day before LCIG, overall time with dyski-
nesia signiﬁcantly increased after 3 months of treatment. In patients
with> 50% of time with dyskinesia before LCIG, periods of trouble-
some dyskinesia were signiﬁcantly reduced, while the percentage of
time with dyskinesia remained the same [74]. These variations might
be partly explained by a narrow therapeutic window and diﬃculty in
achieving an accurate dose adjustment. Also, many patients are titrated
against OFF time, and accept an increase in mild dyskinesia that does
not interfere with daily activities. These results suggest that dyskinesia
is an indication for LCIG. Preliminary results suggest that disease
duration before LCIG may have no impact on dyskinesia outcomes [86],
and long-term improvement has been reported [43].
2.3. Other motor symptoms
Levodopa/carbidopa intestinal gel has also been shown to system-
atically improve eﬃcacy parameters, such as the Uniﬁed Parkinson's
Disease Rating Scale (mostly evaluated in ON). General improvement
with LCIG treatment compared with conventional treatment or baseline
disease activity has been reported [37,38,49,55,92]. This improvement
aﬀects activities of daily living [41,44,49,55,62,70,89], motor symp-
toms [37,49,56,70,82], and motor complications [35,37,38,49,52,55,
56,58,59,62,66]. Improvements in the subscales of activities of daily
living and motor complications are consistent with a longer duration of
dyskinesia-free ON time (allowing for independence in daily activities)
and the reduction of OFF time with LCIG. It is interesting to note,
however, that several studies found no improvement with LCIG in the
motor symptoms subscale [35,44,52,62], usually measured during OFF
time, and a long-term study (up to 2 years follow-up) even reported
worsened symptoms [58]. This underlines the beneﬁt of continuous
infusion of levodopa in order to maintain ON time. Additionally, in 2
short series, treatment with LCIG has been shown to improve freezing of
gait (measured by the speciﬁc questionnaire) in up to 45% of patients
with severe disability due to this complication [68,69]. This improve-
ment was also accompanied by a reduction in falls in one of these
studies [68], and similar results had been previously reported [35].
Motor outcomes in some retrospective and prospective studies have
suggested that starting treatment earlier in younger patients and in
those with shorter disease duration might improve overall outcomes in
patients treated with LCIG [23,47,86] but, as previously noted, there is
conﬂicting evidence, since the 2-year analysis from the GLORIA registry
and the 1-year post-hoc analysis of the open-label phase-III trial have
not found diﬀerential outcomes related to age or disease duration
[87,88]. Some authors have suggested that a long life expectancy might
also be taken into account [90].
2.4. Non-motor complications
Patients with APD may present with cognitive impairment, de-
pression, anxiety, apathy, sleep disorders [93,94], pain, and sensory
and autonomic impairment (such as orthostatic hypotension, geni-
tourinary problems, and constipation). Unfortunately, treatment of
these symptoms is often suboptimal [94,95]. Psychiatric disorders
secondary to dopaminergic treatment are also common, particularly
impulse control disorders (ICDs), such as pathological gambling or
shopping, and psychotic symptoms [90]. These NMS are relevant in
APD, since they intensify as the disease progresses, and may become
incapacitating in advanced stages of the disease [96].
Several open-label studies have evaluated the eﬀect of LCIG treat-
ment on NMS using validated tools, most often the Non-Motor
Symptoms Scale (NMSS). A recent non-randomized open-label trial
reported by Dubow et al. showed a 38.3% improvement in the NMSS
compared to baseline after a mean of 18 ± 106 days of treatment [67],
which is similar to the−41.0% relative change observed in the EuroInf
study [60] after 6 months of treatment with LCIG. However, Fasano
et al. [52] reported a signiﬁcant 14% improvement in the NMSS after a
follow-up of 24 ± 14.4 months. These results are generally consistent
with several other studies [56,62,70,97], and the ﬁnal results of the
GLORIA registry, with a signiﬁcant and persistent reduction in NMSS
score from baseline through month 24 [98]. However, reductions in the
NMSS did not always reach statistical signiﬁcance [35]. Regarding
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studies that did not speciﬁcally use this scale, a general improvement of
81.8% in NMS was reported in a retrospective study [48], as well as in
more speciﬁc NMS (pain, dysphagia, and dysarthria) [47].
2.5. Neuropsychiatric disorders
Improvement of several neuropsychiatric disorders after medium to
long-term treatment (> 2 years) with LCIG has been reported. PD-re-
lated symptoms such as depression [52,83], anxiety, and apathy have
been shown to improve signiﬁcantly [61,78,83]. This could be corre-
lated with better control of motor symptoms, as anxiety (general dis-
order, social phobia, or panic attacks) may be associated with OFF
periods (as non-motor ﬂuctuations), and depression can be inﬂuenced
by the severity of symptoms [99].
Most studies have excluded patients with severe psychiatric dis-
orders; however, some patients with psychosis (particularly drug-in-
duced) [4,46,78,90], and hallucinations [47,61,83,97,100] have been
successfully treated, and either improved or did not worsen
[46,101–103]. Therefore, patients with psychiatric disorders should be
assessed on a case-by-case basis to determine if therapy with LCIG is
warranted [11], and treatment should be exercised with caution. Some
of these symptoms (e.g., ICDs) often result from or are aggravated (e.g.,
psychosis) by other antiparkinsonian drugs; therefore, discontinuation
of the previous medication (tapering according to label) when initiating
LCIG therapy may be beneﬁcial [52]. Dopamine dysregulation syn-
drome occurred in 3 of 6 patients in a short series [91], and evaluation
of personality traits (i.e., personality that could be predictive of a do-
pamine dysregulation syndrome) has been proposed. The recent E-DUO
study in Spain, a retrospective analysis of 185 patients from 2006 to
2011, provided favorable preliminary evidence of LCIG therapy on
hallucinations in 46.6% of patients and ICDs in 39.4% of patients [61].
Also, infusion therapies (apomorphine and LCIG) may present low risk
of development of ICDs, and preexisting ones were found to improve in
a small prospective study [103].
Recent studies on the use of LCIG suggest that patients with mild to
moderate dementia (if they have a caregiver) [35,47,78,82,97], in-
cluding moderate memory complaints, impaired attention and dis-
orientation, reduced verbal ﬂuency, and organizational abilities
[56,78,84,97], may be candidates for treatment with LCIG. Some au-
thors, however, exclude patients with dementia, or only include pa-
tients with less severe cases of dementia [22,40,52,62]. In LCIG studies,
no worsening of Mini-Mental State Examination scores were noted
during follow-up [22,52]. Treatment with LCIG does not signiﬁcantly
inﬂuence the clinical course of cognitive deterioration, and worsening
of dementia has been reported in the long-term [35,62]. Gastrostomy
and infusion systems are delicate enough; thus, poor medical conditions
or dramatic worsening may contraindicate treatment with LCIG or
advise discontinuation. Therefore, mental performance should be
carefully assessed and taken into account when considering treatment
with LCIG and, in the authors' opinion, the use of LCIG in patients with
severe dementia is currently not recommended.
2.6. Sleep disorders
In patients with APD and sleep disorders, Fasano et al. [52] ob-
served signiﬁcant improvement (14%) in the Parkinson's Disease Sleep
Scale (PDSS) after a follow-up of 24 ± 14.4 months. Similarly, pro-
spective studies have reported a signiﬁcant reduction in sleep disorders
[46,56,63,97]. Treatment with LCIG seems to improve disturbed/frag-
mented sleep [46,82–84], and 24-h infusion has been used with success
in selected patients with sleep disturbances [46]. Favorable results for
LCIG therapy have been reported in detailed sleep-related NMS: in one
report [61], sleep disturbances (insomnia, daytime sleepiness/fatigue,
dystonia) improved in> 50% of patients, and a decrease in insomnia
was also reported after 3 months of treatment with LCIG, which was
related to an improvement in nocturnal akinesia [68]. Also, the 24-
month results of the GLORIA registry showed improvement in each of
the 9 NMSS domain scores and, particularly, the signiﬁcant reduction
observed in sleep/fatigue (24-month value:−5.3 ± 11.1; p < 0.001)
was maintained throughout the study [98].
2.7. Dysautonomic symptoms
The eﬃcacy of treatment with LCIG on cardiovascular symptoms,
urinary and sexual dysfunction, gastrointestinal symptoms (including
dysphagia and constipation), and excessive sweating, among others, has
been varied. In some studies, signiﬁcant improvements have been re-
ported in cardiovascular symptoms [61,97], gastrointestinal symptoms
[97], and in urinary dysfunction [56,97]. Improvements in pain, dys-
phagia, and dysarthria were also noted in one study [47]. However, in a
recent retrospective multicenter E-DUO study exploring the eﬀects of
LCIG on individual symptoms [61], most patients did not experience
changes in urinary symptoms and sexual diﬃculties; some patients re-
ported worsening of these symptoms. Constipation also remained si-
milar in half of the sample. Outcomes in drooling and swallowing
problems were mixed, as similar percentages of patients reported im-
provement, no changes, or worsening of these symptoms. In contrast,
falls and dizziness improved in approximately half of the cohort [61].
In conclusion, although control of NMS is not included among the
main indications of LCIG, evidence suggests that patients experiencing
some of the wide range of NMS in advanced stage PD may experience
beneﬁt from LCIG treatment, and should not be automatically excluded
from oﬀering treatment with LCIG, with the exception of patients with
severe dementia. Psychiatric disorders such as depression, ICDs, or
hallucinations are not an absolute contraindication for treatment with
LCIG. Several studies have excluded these patients, so data on the
treatment of such patients is limited and patients should be assessed on
a case-by-case basis for the suitability of LCIG treatment.
3. Contraindications and exclusion criteria
Labelled contraindications include intolerance to levodopa/carbi-
dopa, narrow-angle glaucoma, severe heart failure, severe arrhythmia,
acute stroke, conditions in which adrenergic drugs are contraindicated,
and concomitant use of MAO inhibitors. Logically, any condition that
contraindicates surgery or gastrostomy makes the patient unsuitable for
this therapy. Generally, advanced age is not an issue, and among cog-
nitive symptoms, in our opinion only severe dementia would exclude
LCIG therapy. In any event, a caregiver capable of handling the device
should be present, and this should be considered as favoring the deci-
sion to start treatment [52], especially in the light of studies showing
the need for a nurse or caregiver to set up the device in the morning and
at other times during the day [47,66].
4. Safety considerations: why and when to discontinue LCIG
(Table 2)
LCIG is a costly treatment and insertion of the device requires a brief
hospital stay, surgery, and close clinical monitoring during the initial
months of therapy [22,23]. Therefore, the likelihood of discontinuation
is an important factor to be considered when selecting patients. Ac-
cording to a Swedish study, the mean treatment duration with LCIG is
approximately 8 years, and in most cases, LCIG therapy is continued
until the death of the patient (for other causes) [53]. LCIG may be
considered a lifelong treatment. According to previous evidence, dis-
continuation (even when due to death) generally occurred in patients of
a more advanced age [47,81]. Clinical observations suggested that
patient age at the time of implant could be related to the risk of dis-
continuation [81], and in light of this information, earlier initiation of
LCIG therapy has been proposed [47,90]. In a study speciﬁcally ad-
dressing the risk of discontinuation, the probability of discontinuation
was not associated with a particular set of baseline clinical and
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demographic characteristics, apart from patient age and longer OFF
time and longer ON time with dyskinesia at baseline [104]. However,
the recently published integrated safety analyses from 4 prospective
clinical trials [105] (963 patient-years of exposure) demonstrated that
age at initiation was not related to discontinuations. Also, patient with a
longer duration presented slightly lower discontinuation rates.
The safety proﬁle of LCIG is similar to that of oral levodopa [83], and
discontinuation due to lack of eﬃcacy, levodopa-induced adverse events, or
symptoms related to disease progression are to be expected. The procedure
involves percutaneous endoscopic gastrostomy (PEG) and the permanent
insertion of an intrajejunal tube. Granuloma and complications related to
the device are the most frequently observed adverse events with LCIG
therapy, may occur in up to 69% of cases in the literature [47,106], and
considered very frequent (≥1/10) according to label. However, procedure-
related problems (duodenal ulcer, stoma infection, granuloma, abdominal
pain, broken connectors, migration of the internal line, or kinks)
[35,47,48,57,61,83] generally do not lead to discontinuation when appro-
priately managed [44,47,67,70], and are often resolved with conservative
treatment (in the case of infections) or tube replacement [35,47,48,57]. The
most important reasons for discontinuation are severe cases of peritonitis or
infection [35,47,53,59,82], and prophylactic antibiotics after PEG are re-
commended to prevent peristomal infections [107,108].
The set of disease- or treatment-related adverse events potentially
leading to discontinuation mainly include neuropsychiatric disorders, but
only a few severe cases of dementia and hallucinations have led to dis-
continuation [44,47]. Peripheral polyneuropathy has been described in
patients on long-term treatment with high doses of oral levodopa
[109,110]. The causes for this remain unclear but, in our opinion, the
clinical situation of acute inﬂammatory demyelinating polyneuropathy
(AIDP) might be considered a relative contraindication for continuation of
LCIG. A recent study by Merola, 2016 et al. [111] has suggested the con-
tribution of homocysteine-mediated neurotoxicity. According to their re-
sults regarding the development of subacute or chronic polyneuropathy in a
small cohort of patients treated with LCIG, the authors considered serial
clinical-electrophysiological evaluations mandatory in patients treated with
LCIG. Many, though not all, of these patients improved with vitamin B12
supplements [35,57,70,92,110], and by adjusting the infusion rate [57];
thus, discontinuation can be avoided except in the most severe cases [110].
Finally, some causes of discontinuation related to disease progres-
sion, such as repeated problems with the infusion system, have been
associated to the development of signiﬁcant cognitive decline and de-
mentia [44,53,58,61]. This supports the recommendation by some au-
thors that LCIG therapy should be initiated early in APD to achieve the
maximum beneﬁt [47]. Indeed, it was suggested that t relatively large
number of discontinuations in studies reﬂects the current trend to use
LCIG in patients with end-stage APD [59].
Importantly, no irreversible sequelae have been reported in patients
who discontinued long-term LCIG therapy [83]. Thus, this should not
be a concern if a moderate probability of discontinuation is taken into
account when considering LCIG therapy for a particular candidate.
5. Assisting the patient: caregiver, multidisciplinary team and
social aspects
Neurodegenerative disorders place a considerable burden on the
individuals involved in caring for patients [16]. Psychological stress
associated with caring for a patient has gained consideration in recent
years, as the role of the main caregiver, usually a family member, is
crucial in this context [16,112–114]. The progressive nature of PD, the
clinical characteristics of the disease (e.g., severity and the level of
disability at a certain point), its unpredictability, and drug adverse
events are among the most inﬂuential factors [112–114].
In the case of treatment with LCIG, the presence of a caregiver
capable of handling the equipment and monitoring complications is
beneﬁcial, and management and maintenance of the pump and daily
care of the stoma require some basic training [82]. A recent report has
indicated that morning set-up of the pump could be performed by the
patient alone in only 6% of cases, while self-administration of extra
doses was possible in 32% [47]. However, 50% of patients in this cohort
were mentally impaired, and these ﬁndings probably reﬂect the lim-
itation of using LCIG therapy in patients with dementia. Additionally,
complications related to gastrostomy and the tubes call for monitoring
by a caregiver. In some studies, the unavailability of a suitable care-
giver is an exclusion criterion in patients with dementia or mild cog-
nitive impairment [35,52,97], while inability of the caregiver to handle
the pump has led to exclusion in others [97]. Therefore, the caregiver
should be capable of handling the equipment, and trained to do so. If no
suitable caregiver is available (e.g., the caregiver is elderly and dis-
abled), the availability of local/community help, such as PD nurses and
trained volunteers, should be explored before considering LCIG
therapy.
Several studies have reported improved patient independence fol-
lowing LCIG therapy. Patients reported signiﬁcantly less need for help
from a caregiver [66,82] (i.e., improved autonomy [over 90%]) [47]
and reported fewer diﬃculties handling their daily chores [40]. This
would suggest that the treatment of patients with APD with LCIG
lightens the burden placed on caregivers. Despite its limitations and
complications, there is no evidence that LGIC therapy worsens patient
QoL or increases caregiver burden. Contrary to this, improvements in
caregiver burden [37,38,115], levels of stress, and QoL (not signiﬁcant)
[35,52,62] have been reported.
Table 2
Summary of most relevant safety issues with levodopa-carbidopa intestinal gel in the literature.
Issue Reported in studies
Device and gastrostomy-related
Technical problems with PEG-tube (dislocation, occlusion, disconnection, accidental removal, etc.) [22,23,31,35,37,41,46,52,58,59,62,66,70,73,74,81,85,92,111]
Technical problems with device (malfunction, breakage or unsatisfactory pump control) [22,31,35,46,70,74]
Local problems related with tube insertion (stoma infection, granuloma) [35,37,58,59,62,66,70,74,81,92,111]
Intestinal perforations due to PEG-tube [22,58,66,74,81]
Non-local infections related to tube insertion (e.g. Peritonitis) [35,41,59,66,81,111]
Medication-related
Sleep disturbances [39,41,74]
Hallucinations, psychosis [35,45,58,59,62,70,74,111]
Confusion [22,39,52]
Neuropathy/polyneuropathy [35,41,52,59,62,66,70,74,81,85]
Weight loss [35,41,46,52,59,66,70,74,111]
Mood disturbances [35,59]
Other problems less-frequently reported
Constipation, abdominal pain, gastric ulcer, bezoar, procedural pain, depression.
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6. Improvements in QoL
Considering its beneﬁts in treating several motor symptoms and
NMS, it is not surprising that LCIG therapy in patients with APD has
been widely shown to be associated with improved QoL, both in clinical
trials and other studies [23,35,38,39,41,45,49,57,66,70,97]. Sustained
improvements in QoL measured by validated tools have been reported
in studies with follow-up periods of up to 2 years [38,40,41,45,52,59].
Most of these studies based their assessment on the Parkinson's Disease
Questionnaire-39. Generally, signiﬁcant improvements were noted both
overall and in particular domains in periods ranging from 6 to
24 months [38,41,44,45,48,49,55,57]. In 2 studies, however, the ob-
served improvements were not statistically signiﬁcant at all time points
[40,55]. Domains that have been observed to improve include sa-
tisfaction with mobility [23,40,41,44,57,62], overall functioning,
ability to carry out daily chores [23,40,41,44,57], sense of stigma
[23,41,44], and cognition [23,41,49]. After a mean follow-up of
36 months, a study reported overall improvement in patients as mea-
sured using the Parkinson's Disease Questionnaire-39, except for “cog-
nition” [58]. Consistent with these ﬁndings, studies that assessed pa-
tients using the Parkinson's Disease Questionnaire-8 reported similar
results [35,56,59,70,97] after 6 months of treatment. These ﬁndings
correlate with improvements in motor symptoms and NMS [35,97]. In
studies in which patient QoL was assessed, the majority of patients
reported improvements, with> 90% of cases in one multicenter study
[47] and 100% in another reporting improved QoL [66]. Improvements
in quality of life, as measured by PDQ-8, and activities of daily living
have been reported as independent of the patient's age (< or
≥65 years) or disease duration (< 10 or ≥10 years) at baseline [87].
7. Discussion and conclusions
Despite several suggested approaches in the literature, there are no
deﬁnitive criteria for selection of patients with APD as suitable candi-
dates for each of the currently available device-aided treatment alter-
natives. While clinical indications may overlap in some patients, ex-
clusion criteria diﬀer for each technique. Overall, the decision depends
on many factors, including the characteristics of the patient, family
support, and the preferences of both the patient and their caregivers. It
is our opinion that some basic characteristics, however, are applicable
to candidates for all 3 treatment alternatives (LCIG, DBS, and con-
tinuous subcutaneous infusion of apomorphine):> 1–2 h of disabling
OFF time [19] and good ON time quality, with mild to moderate dys-
kinesia, largely refractory to conventional oral treatment, and mild or
no cognitive impairment. Indeed, signs that optimized conventional
therapies are no longer providing symptom control should be identiﬁed
before considering advanced therapies [11,18].
Clinical observations by Calandrella et al. suggested that patient
age > 70 years at implant was associated with discontinuation of LCIG
therapy [81]. However, more recent evidence from the integrated
safety analyses from 4 prospective clinical trials [105] indicated there
was no impact of age on discontinuations and, regarding disease
duration. Therefore, this treatment can also be considered in the ger-
iatric population, particularly since other treatment alternatives are
inapplicable. Similarly, there are no limits regarding disease duration at
the initiation of LCIG therapy. Most of the studies reviewed in this
paper enrolled patients with a long duration of disease (> 10 years). In
a national retrospective study, disease duration > 10 years was asso-
ciated with a poorer outcome in terms of motor disability compared
with patients with a shorter disease duration, although this does not
seem to aﬀect motor complications such as dyskinesia [86]. Con-
sidering the deterioration in cognition with disease progression, some
authors have proposed that implementing LCIG early may be associated
with greater LCIG clinical beneﬁt [23,35,47]. This hypothesis was not
conﬁrmed by results of a recent post-hoc analysis of the patients en-
rolled in the open-label phase-3 study and in the GLORIA registry al-
though this may be related to the small sample size in most subgroups
[87,88]. The suitable candidate for LCIG would be a relatively young
patient suboptimally controlled with conventional therapy and with a
good cognitive status whose QoL would be signiﬁcantly improved with
the control of APD symptoms [23]. However, older patients even with
impaired gait, freezing episodes, and mild cognitive impairment may
also ﬁnd beneﬁt with LCIG therapy (see Table 3 for a summary of in-
dications and contraindications). Treatment with LCIG provides in-
creased overall QoL in patients with APD and potentially relieves some
caregiver burden. Improvements in mobility and activities of daily
living are particularly signiﬁcant. Some dopamine-responsive NMS
seem to improve with LCIG treatment, and patients with severe sleep
disorders despite oral treatment, including nocturnal dystonic pain and
akinesia, might beneﬁt from 24-h treatment with LCIG [56,82,116]
Several studies suggest that certain patients with a wide spectrum of
motor complications may also beneﬁt from treatment with LCIG, as
some complications improve with therapy (e.g., freezing, tremor, falls,
dysphagia [35,47,61,106]) and the motor subscale in the Uniﬁed Par-
kinson's Disease Rating Scale has been consistently shown to improve
[38,52,66]. Regarding the risk of discontinuation, some aspects related
to the lack of eﬃcacy or neuropsychiatric disorders may be minimized
with careful selection of candidates.
In conclusion, any patient with APD (i.e., in whom optimal control
with conventional oral treatment cannot be achieved) with a relatively
preserved cognitive–behavioral status and good family/caregiver sup-
port, who is not likely to be particularly susceptible to safety concerns
that commonly lead to premature discontinuation, would be a candi-
date for treatment with LCIG.
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